Neol Bio has a team of over 35 professionals capable of developing the most advanced microbiological technologies in order to carry out high value added solutions.
The management team of Neol Bio is made up of reference professionals from the sector and combines the necessary competencies of management, research and commercial skills to promote the company’s growth and development.
The assets of the scientific-technical team include advanced industrial knowledge and a wealth of experience in the fields of microbiology, molecular biology, bioprocess engineering and chemical engineering.
Chairman: Jose Manuel Arrojo
Chartered accountant and financial analyst. Expert in restructurings, corporate operations (mergers, acquisitions) and advisory services for growing companies. Independent director of Alza Real Estate S.A. and independent director of the financial services group GVC Gaesco. He has been a member of the Boards of Directors of various quoted and non-quoted companies (Iberclear, Bolsas y Mercados, Unión Fenosa, Amper, Service Point, Vértice) and is also a member of the executive management of Unión Fenosa, Grupo Banco de Santander and Arthur Andersen among others.
Chief Executive Officer (CEO): Javier Velasco (CEO), PhD
Over 10 years of experience in management of biotechnological companies. He has been the CEO of Neuron Bio since its foundation to 2012, thus contributing to its establishment, development and its IPO at the Spanish Alternative Stock Market (MAB). Previously he led the biotechnology department of Puleva Biotech and was a researcher at GlaxoSmithKline and Antibioticos SA. Expert in valuation of technologies and biotech companies and in management of IP portfolio.
Chief Scientific Officer (CSO): José Adrio, PhD
Internationally renowned researcher with particular expertise in industrial biotechnology (over 40 publications in scientific journals and books in the field, inventor of over 10 patents). Postdoctoral researcher at the MIT (Boston, USA). Experience in R&D management at various companies (Neuron BioIndustrial, Puleva Biotech and Antibioticos SAU).
Chief Financial Officer (CFO): Consuelo García-Liria
Economist and account auditor. Previous extensive experience as CFO in biotech companies, from start-up to going public. Expert in financing R&D projects and treasury management.